ArticleFrontiers in molecular biosciences2026
Variant allele frequency as a predictor of treatment response to osimertinib in EGFR-mutated NSCLC.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of Variant Allele Frequency (VAF) Levels on Clinical Efficacy of Osimertinib in Patients with Metastatic NSCLC.Medical sciences (Basel, Switzerland) · 2026Review
- Impact of EGFR variant allele frequency on treatment-related adverse events in patients with metastatic NSCLC treated with osimertinib.Frontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osimertinib has been approved as a treatment option for epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC). However, despite the identification of common mutations, there are still no additional pathological factors that can be used to predict treatment response and improvement in survival. Methods: This retrospective study utilized data from a multi-center registry of NSCLC patients with EGFR mutations who were treated with first-line osimertinib therapy between March 2017 and December 2024. The variant allele frequency (VAF) was evaluated as a potential predictive factor for overall survival (OS). Results: For the cohort of 147 patients who met eligibility requirements, the mean OS was 25.5 months (95% CI 20.28-30.75) and progression-free survival (PFS) was 21.4 months (95% CI 17.38-25.37). The mean OS was 19.7 months (95% CI 14.21-25.10) for VAF <30% and 31.4 months (95% CI 23.15-39.56) for VAF ≥30%. The mean PFS was 18.2 months (95% CI 12.94-23.46) for VAF <30% and 25.0 months (95% CI 19.14-30.94) for VAF ≥30%. In the subgroup of EGFR ex 19del the mean OS was 21.1 months (95% CI 11.04-31.25) for VAF <30% and 36.6 months (95% CI 25.61-47.50) for VAF ≥30% and for the subgroup with EGFR ex21 L858R the mean OS was 18.7 months (95% CI 12.36-25.00) for VAF <30% and 25.5 months (95% CI 13.78-37.22) for VAF ≥30%. Conclusion: Our study demonstrated that the VAF is a significant factor in predicting OS and PFS in EGFR mutant patients treated with osimertinib. Patients with a VAF ≥30% showed significantly improved OS and PFS compared to those with a VAF <30%. Specifically, the mean OS was longer for patients with higher VAF in both the overall cohort and in subgroups with EGFR exon 19 deletions and exon 21 L858R mutations. These findings suggest that VAF could serve as a valuable predictive biomarker for treatment outcomes in EGFR-mutated NSCLC patients, highlighting its potential role in personalizing treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.